Brain tumor vaccine has promising results

Nov 22, 2006

U.S. cancer researchers say a vaccine for treating a recurrent brain cancer known as glioma has shown promising results in preliminary clinical trials.

Findings from the first group of six patients in the study -- being conducted at the University of California-San Francisco's Brain Tumor Research Center -- involved vitespen (trademarked as Oncophage), a vaccine made from the patient's own tumor.

The trial's preliminary results indicate the vaccine was associated with tumor-specific immune response in patients with recurrent, high-grade glioma.

Glioma is a type of primary tumor that arises from the glial cells -- the connective tissue cells that surround and support nerve cells. The most common site of involvement of a glioma is the brain. Malignant glioma is currently a fatal disease.

"This is the first documentation of a glioma-specific immune response after vaccination with vitespen," said Dr. Andrew Parsa, assistant professor in the University of California-San Francisco Department of Neurological Surgery and principal investigator of the trial. Based on the preliminary findings, a larger phase 2 study is planned for 2007.

The trial results were presented last week in Orlando, Fla., during a meeting sponsored by the Society of Neuro-Oncology.

Copyright 2006 by United Press International

Explore further: Booming mobile health app market needs more FDA oversight for consumer safety, confidence

add to favorites email to friend print save as pdf

Related Stories

Brain tumor vaccine trial shows promising results

Apr 16, 2007

A vaccine for treating a recurrent cancer of the central nervous system that occurs primarily in the brain has shown promise in preliminary data from a clinical trial at the University of California, San Francisco.

Poll: Big Bang a big question for most Americans

Apr 21, 2014

Few Americans question that smoking causes cancer. But they have more skepticism than confidence in global warming, the age of the Earth and evolution and have the most trouble believing a Big Bang created the universe 13.8 ...

Climate conditions help forecast meningitis outbreaks

Mar 18, 2014

Determining the role of climate in the spread of certain diseases can assist health officials in "forecasting" epidemics. New research on meningitis incidence in sub-Saharan Africa pinpoints wind and dust ...

A tiny, time-released treatment

Oct 09, 2013

Omid Farokhzad's vision of medicine's future sounds a lot like science fiction. He sees medicine scaled down, with vanishingly small nanoparticles playing a big role, delivering drug doses measured in molecules ...

Study turns parasite invasion theory on its head

Dec 23, 2012

Current thinking on how the Toxoplasma gondii parasite invades its host is incorrect, according to a study published today in Nature Methods describing a new technique to knock out genes. The findings coul ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

User comments : 0